Evidence map›Paper›PMID 28109960›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2017

RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21.

Tae Jin Lee, Ji Young Yoo, Dan Shu, Hui Li, Jianying Zhang, Jun-Ge Yu, Alena Cristina Jaime-Ramirez, Mario Acunzo, Giulia Romano, Ri Cui and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 1 synthesis or guideline pooled it, 144 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Cell and gene therapy in neuro-oncology.Handbook of clinical neurology · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Tae Jin LeeDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
Ji Young YooDepartment of Neurological Surgery, College of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
Dan ShuDivision of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA; Department of Physiology and Cell Biology, Dorothy M. Davis Heart and Lung Research Institute, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Hui LiDivision of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA; Department of Physiology and Cell Biology, Dorothy M. Davis Heart and Lung Research Institute, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Jianying ZhangDepartment of Biomedical Informatics, Center for Biostatistics, Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH 43210, USA.
Jun-Ge YuDepartment of Otolaryngology, Head & Neck Surgery, The Ohio State University Medical Center, Columbus, OH 43210, USA.
Alena Cristina Jaime-RamirezDepartment of Neurological Surgery, College of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
Mario AcunzoDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
Giulia RomanoDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
Ri CuiDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
Hui-Lung SunDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
Zhenghua LuoDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
Matthew OldDepartment of Otolaryngology, Head & Neck Surgery, The Ohio State University Medical Center, Columbus, OH 43210, USA.
Balveen KaurDepartment of Neurological Surgery, College of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
Peixuan GuoDivision of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA; Department of Physiology and Cell Biology, Dorothy M. Davis Heart and Lung Research Institute, College of Medicine, The Ohio State University, Columbus, OH 43210, USA. Electronic address: guo.1091@osu.edu.
Carlo M CroceDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA. Electronic address: carlo.croce@osumc.edu.
The Ohio State University · USNeurological Surgery · USThe Ohio State University Wexner Medical Center · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
The Tumor Microenvironmental Barrier to Effective Viral OncolysisP01CA163205 · NCI · OHIO STATE UNIVERSITY · PI MICHAEL A CALIGIURI · 2013 to 2026
$26.0M
Cancer Gene Discovery to Identify Targetable TargetsR35CA197706 · NCI · OHIO STATE UNIVERSITY · PI CROCE, CARLO M · 2015 to 2021
$6.4M
Enhancing Viral Oncolysis with Vasculostatin Gene DeliveryR01CA150153 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KAUR, BALVEEN · 2011 to 2020
$4.0M
OV Therapy Induced Changes in Tumor Secretome and Their Impact on TherapyR01NS064607 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KAUR, BALVEEN · 2008 to 2018
$3.2M
Echogenic Polymersomes for Triggered Contents ReleaseR01GM114080 · NIGMS · NORTH DAKOTA STATE UNIVERSITY · PI MALLIK, SANKU, SARKAR, KAUSIK · 2015 to 2023
$2.6M
Molecular Mechanisms of Cachexia in Lung CancerR01CA190740 · NCI · OHIO STATE UNIVERSITY · PI CROCE, CARLO M, NANASINKAM, SERGE PATRICK · 2015 to 2019
$2.1M
RNA Nanotechnology in Cancer TherapyU01CA151648 · NCI · UNIVERSITY OF KENTUCKY · PI GUO, PEIXUAN, LI, HENRY · 2010 to 2014
$2.1M
RNA Therapeutics for Targeted Treatment of Colon CancerR01CA186100 · NCI · UNIVERSITY OF HOUSTON · PI GUO, BIN · 2015 to 2018
$1.4M
Oncolytic virotherapy and immunotherapy in the treatment of brain tumorsF32CA186542 · NCI · OHIO STATE UNIVERSITY · PI JAIME-RAMIREZ, ALENA CRISTINA · 2015 to 2016
$113k
NCI NIH HHS F32 CA186542NCI NIH HHS P01 CA163205NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA150153NCI NIH HHS R01 CA186100NCI NIH HHS R01 CA190740NCI NIH HHS R35 CA197706NCI NIH HHS U01 CA151648NIGMS NIH HHS R01 GM114080NINDS NIH HHS R01 NS064607
6 · The paper itself

Abstract

Targeted inhibition of oncogenic miRNA-21 has been proposed to treat glioblastoma by rescuing tumor suppressors, PTEN and PDCD4. However, systemic delivery of anti-miR-21 sequences requires a robust and efficient delivery platform to successfully inhibit this druggable target. Three-way-junction (3WJ)-based RNA nanoparticles (RNP), artificially derived from pRNA of bacteriophage phi29 DNA packaging motor, was recently shown to target glioblastoma. Here, we report that multi-valent folate (FA)-conjugated 3WJ RNP constructed to harbor anti-miR-21 LNA sequences (FA-3WJ-LNA-miR21) specifically targeted and delivered anti-miR-21 LNA and knocked down miR-21 expression in glioblastoma cells in vitro and in vivo with favorable biodistribution. Systemically injected FA-3WJ-LNA-miR21 RNP efficiently rescued PTEN and PDCD4, resulting in glioblastoma cell apoptosis and tumor growth regression. Overall survival rate was also significantly improved by FA-3WJ-LNA-miR21 RNP. These results are indicative of the clinical benefit of FA-3WJ RNP-based gene therapy for the successful targeted therapy of developing and even recurring glioblastoma.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsAntagomirsApoptosis Regulatory ProteinsBrain NeoplasmsCell Line, TumorDrug CarriersFemaleFolate Receptors, GPI-AnchoredFolic AcidGlioblastomaHumansMiceMice, NudeMicroRNAsNanoparticlesAntagomirsApoptosis Regulatory ProteinsDrug CarriersFolate Receptors, GPI-AnchoredFolic Acidlocked nucleic acidMicroRNAsMIRN21 microRNA, humanOligonucleotidesPDCD4 protein, humanPTEN PhosphohydrolasePTEN protein, humanRNA-Binding Proteins3WJapoptosisglioblastomamicroRNARNA nanoparticle

Identifiers

PMID28109960
PMCPMC5498802
OpenAlexW2573318906

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.